Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

Journal of Cellular Physiology

Volumn 195, Issue 1, 2003, Pages 139-150

  Di Gennaro, Elena ^a   Barbarino, Marcella ^a,d   Bruzzese, Francesca ^a   De Lorenzo, Sonya ^b   Caraglia, Michele ^c   Abbruzzese, Alberto ^c   Avallone, Antonio ^a   Comella, Pasquale ^a   Caponigro, Francesco ^a   Pepe, Stefano ^b   Budillon, Alfredo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN P21; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CDK2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; PROTEIN SERINE THREONINE KINASE; QUINAZOLINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UPREGULATION; BIOSYNTHESIS; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK TUMOR; MACROMOLECULE; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; MACROMOLECULAR SUBSTANCES; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0037374686     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.10239     Document Type: Article

References (82)

1. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. 2001. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61:6500-6510.
2. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. 2002. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20:110-124.
3. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S, Fusco A, Viglietto G. 1999. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 104:865-874.
4. Baldassarre G, Boccia A, Bruni P, Sandomenico C, Barone MV, Pepe S, Angrisano T, Belletti B, Motti ML, Fusco A, Viglietto G. 2000. Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. Cell Growth Differ 11:517-526.
5. Baselga J. 2001. Targeting the epidermal growth factor receptor: A clinical reality. J Clin Oncol 19(Suppl 18):41S-44S.
6. Baselga J, Yano S, Giaccone G, Nakagawa K, Tamura T, Douillard J, Nishiwaki Y, Vansteenkiste JF, Kudou S, Rischin D, Eek RW, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Fukuoka M. 2001. Initial results from a phase II trial of ZD1839 (Iressa) as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). Clin Cancer Res 7(Suppl):630A (abstract).
7. Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV, Bates SE. 2002. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 21(1):119-127.
8. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M. 1999. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 18:5321-5333.
9. Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK, Arteaga CL. 2000. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275:6987-6995.
10. Cantrell DA. 2001. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 114:1439-1445.
11. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. 1999. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: A prognostic factor independent of Ras. Cancer Res 59:684-688.
12. Choudhury GG. 2001. Akt serine threonine kinase regulates platelet-derived growth factor-induced DNA synthesis in glomerular mesangial cells: Regulation of c-fos AND p27(kip1) gene expression. J Biol Chem 276:35636-35643.
13. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063.
14. Claassen GF, Hann SR. 2000. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta-induced cell-cycle arrest. Proc Natl Acad Sci USA 97:9498-9503.
15. D'Agnano I, Valentini A, Fornari C, Bucci B, Starace G, Felsani A, Citro G. 2001. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels. Oncogene 20:2814-2825.
16. Dang CV. 1999. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19:1-11.
17. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three Akts. Genes Dev 13:2905-2927.
18. Elledge SJ, Winston J, Harper JW. 1996. A question of balance: The role of cyclin-kinase inhibitors in development and tomorigenesis. Trends Cell Biol 6:388-392.
19. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A. 1997. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57:3381-3385.
20. Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F, Milano G. 1999. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 79:1864-1869.
21. Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J. 1997. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res 3:1943-1948.
22. Forastiere AA. 1999. Head and neck. Curr Opin Oncol 11:175-176.
23. Gartel AL, Tyner AL. 1999. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 246:280-289.
24. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. 1999. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer 83:235-241.
25. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. 2000. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 275:39223-39230.
26. Hackel PO, Zwick E, Prenzel N, Ullrich A. 1999. Epidermal growth factor receptors: Critical mediators of multiple receptor pathways. Curr Opin Cell Biol 11:184-189.
27. Hunter T, Pines J. 1994. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573-582.
28. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ, Fontana JA. 1997. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 74:529-534.
29. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y. 1997. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15:629-637.
30. Kerkhoff E, Rapp UR. 1998. Cell cycle targets of Ras/Raf signalling. Oncogene 17:1457-1462.
31. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, Zhao M, Miyauchi M, Nikai H. 2000. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 6:916-923.
32. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862.
33. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. 2000. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor over-expression does not determine growth dependency. Mol Cell Biol 20:3210-3223.
34. Lango MN, Shin DM, Grandis JR. 2001. Targeting growth factor receptors: Integration of novel therapeutics in the management of head and neck cancer. Curr Opin Oncol 13:168-175.
35. Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. 2000. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice. Proc Natl Acad Sci USA 97:9609-9614.
36. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. 2001. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res 61:6583-6591.
37. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. 2001. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802-808.
38. Litvak DA, Papaconstantinou HT, Ko TC, Townsend CM, Jr. 1998. A novel cytotoxic agent for human carcinoid tumors. Surgery 124:1071-1076.
39. Liu Y, Martindale JL, Gorospe M, Holbrook NJ. 1996. Regulation of p21WAF1/CIP1 expression through mitogen-activated protein kinase signaling pathway. Cancer Res 56:31-35.
40. Liu X, Sun Y, Ehrlich M, Lu T, Kloog Y, Weinberg RA, Lodish HF, Henis YI. 2000. Disruption of TGF-beta growth inhibition by oncogenic ras is linked to p27Kip1 mislocalization. Oncogene 19:5926-5935.
41. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234.
42. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B, Jacks T. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9:935-944.
43. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakidis TR, Roberts JM. 2001. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 413:323-327.
44. Masciullo V, Ferrandina G, Pucci B, Fanfani F, Lovergine S, Palazzo J, Zannoni G, Mancuso S, Scambia G, Giordano A. 2000. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: Multivariate analysis. Clin Cancer Res 6:4816-4822.
45. Mendelsohn J, Baselga J. 2000. The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565.
46. Mineta H, Miura K, Suzuki I, Takebayashi S, Amano H, Araki K, Harada H, Ichimura K, Wennerberg JP, Dictor MR. 1999. Low p27 expression correlates with poor prognosis for patients with oral tongue squamous cell carcinoma, Cancer 85:1011-1017.
47. Moffatt KA, Johannes WU, Hedlund TE, Miller GJ. 2001. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res 61:7122-7129.
48. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. 1999. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13:1181-1189.
49. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A, Miller P. 1997. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848.
50. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T. 1997. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272:22199-22206.
51. Newman L, Xia W, Yang HY, Sahin A, Bondy M, Lukmanji F, Hung MC, Lee MH. 2001. Correlation of p27 protein expression with HER-2/neu expression in breast cancer. Mol Carcinog 30:169-175.
52. Nigg EA. 1995. Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle. Bioessays 17:471-480.
53. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. 1996. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 56:3666-3669.
54. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. 1999. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 18:5310-5320.
55. Philipp-Staheli J, Payne SR, Kemp CJ. 2001. p27(Kip1): Regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264:148-168.
56. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM. 1997. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225.
57. Pruneri G, Pignataro L, Carboni N, Buffa R, Di Finizio D, Cesana BM, Neri A. 1999. Clinical relevance of expression of the CIP/KIP cell-cycle inhibitors p21 and p27 in laryngeal cancer. J Clin Oncol 17:3150-3159.
58. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H, Rowinsky EK. 2002. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250.
59. Rivard N, Boucher MJ, Asselin C, L'Allemain G. 1999. MAP kinase cascade is required for p27 downregulation and S phase entry in fibroblasts and epithelial cells. Am J Physiol 277:C652-C664.
60. Schlessinger J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-225.
61. Sgambato A, Migaldi M, Faraglia B, Garagnani L, Romano G, De Gaetani C, Ferrari P, Capelli G, Trentini GP, Cittadini A. 1999. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 59:3245-3250.
62. Sherr CJM. 2000. The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res 60:3689-3695.
63. Sherr CJ, Roberts JM. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163.
64. Sherr CJ, Roberts JM. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
65. Shi W, Fan H, Shum L, Derynck R. 2000. The tetraspanin CD9 associates with transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor activation and cell proliferation. J Cell Biol 148:591-602.
66. Sidransky D. 1997. Cancer of the head and neck. In: De Vita WS, Hellman S, Jr., Rosemberg SA, editors. Cancer: Principles & practice of oncology, 5th edition. Lippincott: Philadelphia. p 735-740.
67. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. 2000. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892.
68. Skarpen E, Johannessen LE, Bjerk K, Fasteng H, Guren TK, Lindeman B, Thoresen GH, Christoffersen T, Stang E, Huitfeldt HS, Madshus IH. 1998. Endocytosed epidermal growth factor (EGF) receptors contribute to the EGF-mediated growth arrest in A431 cells by inducing a sustained increase in p21/CIP1. Exp Cell Res 243:161-172.
69. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
70. Taylor WR, Stark GR. 2001. Nucleotide, protein regulation of the G2/M transition by p53. Oncogene 20:1803-1815.
71. Testa JR, Bellacosa A. 2001. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98:10983-10985.
72. Wakasugi E, Kobayashi T, Tamaki Y, Ito Y, Miyashiro I, Komoike Y, Takeda T, Shin E, Takatsuka Y, Kikkawa N, Monden T, Monden M. 1997. p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 107:684-691.
73. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. 1995. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci USA 92:3318-3322.
74. Wilkinson MG, Millar JB. 2000. Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J 14:2147-2157.
75. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. 2002. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86:1157-1161.
76. Woodburn JR. 1999. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250.
77. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J. 1996. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12:1397-1403.
78. Yang HY, Zhou BP, Hung MC, Lee MH. 2000. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin -dependent kinase inhibitor p27. J Biol Chem 275:24735-24739.
79. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, Sonenshein GE. 2001. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20:1688-1702.
80. Yarden Y, Sliwkowski MX. 2001. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
81. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. 2001. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3:245-252.
82. Zhu X, Kwon CH, Schlosshauer PW, Ellenson LH, Baker SJ. 2001. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 61:4569-4575.